KLRS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 17, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Kalaris Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Aug 11, 2026

8-K

Kalaris Therapeutics Announces Executive Leadership Changes

Jul 20, 2026

8-K

Kalaris Therapeutics Reports Positive Expanded Phase 1a SAD Results for TH103 in Neovascular AMD

Jul 17, 2026

8-K

Kalaris Therapeutics Announces Board of Directors Changes

Jul 6, 2026

8-K

Kalaris Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 4, 2026

8-K

Kalaris Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

May 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

April 2026 ATM | Offering amount: $100,000,000 | Bank: TD Securities (USA) LLC

Apr 13, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 5,000,000

Apr 13, 2026

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Feb 28, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Feb 10, 2025

425

Form 425 - Prospectuses and communications, business combinations

Jan 15, 2025

425

Form 425 - Prospectuses and communications, business combinations

Jan 10, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-3

April 2026 SHELF + ATM

Apr 3, 2026

S-3

SHARE RESALE REGISTRATION

Apr 3, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 17, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 4, 2025

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Feb 3, 2025

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Jan 17, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 1, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 1, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Dec 6, 2024

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Nov 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

Coastlands Capital LP (Filed by)

Oct 26, 2026

Vandekop Amy O'Leary (Reporting)

Aug 28, 2026

KEATING LAURIE (Reporting)

Aug 3, 2026

KEATING LAURIE (Reporting)

Aug 3, 2026

Vandekop Amy O'Leary (Reporting)

Jul 27, 2026

Bayko Liisa Ann (Reporting)

Jul 20, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 14, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 14, 2026

CORRESP

Form CORRESP - Correspondence

Apr 9, 2026

CORRESP

Form CORRESP - Correspondence

Apr 9, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 8, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 8, 2026

Kalaris Therapeutics Inc KLRS · SEC Filings